Verrica Pharmaceuticals Inc.
VRCA
$4.18
$0.092.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 269.35% | 899.71% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 269.35% | 899.71% | |||
| Cost of Revenue | -14.00% | -78.17% | |||
| Gross Profit | 1,343.18% | 105.92% | |||
| SG&A Expenses | 0.05% | -10.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.26% | -0.87% | |||
| Operating Income | 118.57% | 28.22% | |||
| Income Before Tax | 102.09% | 39.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 102.09% | 39.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 102.09% | 39.87% | |||
| EBIT | 118.57% | 28.22% | |||
| EBITDA | 120.45% | 28.21% | |||
| EPS Basic | 102.09% | 57.32% | |||
| Normalized Basic EPS | 102.09% | 57.10% | |||
| EPS Diluted | 101.95% | 57.32% | |||
| Normalized Diluted EPS | 102.09% | 57.10% | |||
| Average Basic Shares Outstanding | 0.05% | 40.86% | |||
| Average Diluted Shares Outstanding | 0.07% | 40.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||